secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2024-02-01T23:59:59+00:00
Accession:  0001213900-24-009034
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity: Novartis terminates dovitinib license; director Cullem resigns citing misconduct
--------------------------------------------------------------------------------

- Novartis terminated dovitinib license on Jan 26, 2024 citing material breach for lack of payment.
- Director James G. Cullem resigned Jan 27, 2024, alleging acts and omissions by Chairman and Board injurious to company.
- Cullem was terminated as CEO for cause on Dec 8, 2023; he claims termination should be without cause.
- Allarity disagrees with Cullem's claims and takes exception to his characterizations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390024009034/0001213900-24-009034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390024009034/ea192600-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-009034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer